Nuventra Pharma Sciences is now Allucent. Learn more here.

Take a deeper dive

Events

Navigating Regulatory Strategies for Cellular & Gene Therapies

This event has passed. See all of our upcoming events, browse our Webinar Library for past presentations or, check out our Resource Library for blogs, case studies, news, toolkits and more. 


Join us on February 16th at 1:00pm ET for a webinar discussing key regulatory strategies important to first-in-human trials for cellular and gene therapies. Brandon Burch, Ph.D., Director of Scientific Writing & Regulatory Affairs and William Lee, Ph.D., Vice President of Cell and Gene Therapy Development will lead the session.

While any drug development program can face regulatory hurdles, developing cellular and gene therapies often presents unique challenges. As knowledge and experience expand in this area, the FDA and global regulatory agencies continue to assess and refine their thinking on how to regulate and guide the development of these innovative treatments.

Small and midsize biotech and pharma companies developing cellular and gene therapies should begin to understand critical nuances for successful regulatory meetings and submissions and how they impact strategic decisions during the product development lifecycle. At the end of this webinar, attendees should have a better understanding of:

  • Regulatory requirements to initiate clinical trials for cellular and gene therapy submissions in the US and EU
  • Differences in product submissions for cellular and gene therapies vs. small molecule drugs
  • How to apply the Target Product Profile to guide product development

This event is free of charge.


Meet the Presenters

Brandon Burch, M.S., Ph.D.
Director, Scientific Writing & Regulatory Affairs

Dr. Burch has over 8 years of experience with a primary focus on regulatory affairs, medical and scientific writing, and project management. Dr. Burch has participated in numerous IND, NDA (505(b)(1) and 505(b)(2)), and BLA submissions across a multitude of therapeutic areas and drug classes, including cellular therapies. Dr. Burch’s experience includes overall regulatory strategy; FDA meeting support; program assessments; regulatory submission authoring; and authoring a diverse array of other regulatory, scientific, and technical documents.

William Lee, Ph.D.
Vice President, Cell and Gene Therapy Development

Dr. Lee has over 25 years of research and industrial experience in gene therapy, cellular immunology, and therapeutic vaccines, and 15 years in regulatory affairs. He has worked on Phase I and Phase II clinical study design for devices, small molecule drugs, and biologics. Dr. Lee is also experienced in the writing, design, and execution of pre-clinical studies, and the preparation of Investigational New Drug applications.

Back